KALAMAZOO, MI -- Scientists at Western Michigan University Homer Stryker School of Medicine (WMed) have made a ...

KDIGO guideline is the first specifically addressing autosomal dominant polycystic kidney disease (ADPKD) and focuses on some unique aspects of management.

A research team at Western Michigan University Homer Stryker M.D. School of Medicine has made a significant discovery.

ADPKD, or autosomal dominant polycystic kidney disease, can cause severe pain, headaches, and more problems. What can you do to feel better and stay active? Find exercise and diet tips ...

The case was a tricky one, a surgery was inevitable. The patient had lost a lot of blood. He was also in severe pain. Then, ...

SAN DIEGO - Regulus Therapeutics Inc . (NASDAQ:RGLS), a biopharmaceutical company currently trading at $1.17 per share, today announced significant clinical and regulatory advancements in its ...

(RTTNews) - Regulus Therapeutics Inc. (RGLS) Wednesday announced positive clinical as well as regulatory updates from its autosomal dominant polycystic kidney disease (ADPKD) program.

A team of researchers at Western Michigan University's Homer Stryker M.D. School of Medicine has made a monumental ...

Jason Yondura’s cellphone rings, and the caller has a number he doesn’t recognize. Though it’s most likely a spam call, ...

Regulus Therapeutics Inc . (NASDAQ:RGLS) stock has reached a new 52-week low, touching down at $1.16. This latest price ...

Using a handheld dynamometer to assess hip flexion and abduction strength during dialysis was reliable and safe, researchers found in a cross-sectional study.“Subjects in stages 3 and 4 of [chronic ...

In an indication that has proved difficult for biopharma to conquer, Regulus Therapeutics Inc. disclosed further positive data from its ongoing phase Ib study testing RGLS-8429 in autosomal dominant ...